In patients with early onset, non-systemic, ANA positive oligo or polyarticular JIA with active arthritis on MTX requiring biologic therapy, several pediatric rheumatologists may not feel at ease to introduce etanercept, which is a very effective treatment of arthritis but has no effect on uveitis, unless they are sure that the child will benefit from a proper follow-up by an ophthalmologist, that should involve slit-lamp examination every 3 months during the first 5 years of the disease, in order to detect at an early stage the possible occurrence of uveitis [8]. The gene discussed is BTG3; the disease is juvenile idiopathic arthritis.